Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment

Nature Biotechnology

Volumn 17, Issue 10, 1999, Pages 984-988

  Birchler, Manfred ^a   Viti, Francesca ^a   Zardi, Luciano ^b   Spiess, Bernhard ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Angiogenesis; ED B domain; Fibronectin isoform; Photo dynamic therapy; Recombinant antibody

Indexed keywords

ANTIBODY; FIBRONECTIN; PHOTOSENSITIZING AGENT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BACTERIOPHAGE; CONTROLLED STUDY; ENDOTHELIUM CELL; EYE DISEASE; FEMALE; IMMUNOCHEMISTRY; IRRADIATION; LASER COAGULATION; LIGHT; MOLECULE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RABBIT; RETINA BLOOD VESSEL OCCLUSION; TARGET ORGAN;

EID: 0032827243     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/13679     Document Type: Article

References (32)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumathoid and other disease. Nat. Med. 1, 27-31 (1995).
2. Risau, W. Mechanisms of angiogenesis. Nature 386, 671-674 (1997).
3. Lee, P., Wang, C.C. & Adamis, A.P. Ocular neovascularization: an epidemiologic review. Surv. Ophthalmol. 43, 245-269 (1998).
4. 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA 93, 9764-9769 (1996).
5. Zettar, B.R. On target with tumor blood vessel markers. Nat. Biotechnol. 15, 1243-1244 (1997).
6. Huang, H. et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor neo-vasculature. Science 275, 547-550 (1997).
7. Arap, W., Pasqualini, R. & Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380 (1998).
8. Zardi, L. et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 6, 2337-2342 (1987).
9. Castellani, P. et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59, 612-618 (1994).
10. Carnemolla, B. et al. High-affinity human recombinant antibodies to the oncofetal angiogenesis marker fibronectin ED-B domain. Int. J. Cancer 68, 397-405 (1996).
11. Neri, D. et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat. Biotechnol. 15, 1271-1275 (1997).
12. Pini, A., et al. Design and use of a phage-display library: human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. 273, 21769-21775 (1998).
13. Tarli, L. et al. A high affinity human antibody that targets tumoural blood vessels. Blood 94, 192-198 (1999).
14. Viti, F., Tarli, L., Giovannoni, L., Zardi, L. & Neri, D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of turmoral angiogenesis antibodies. Cancer Res. 59, 347-352 (1999).
15. Winter, G., Griffiths, A.D., Hawkins, R.E. & Hoogenboom, H.R. Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455 (1994).
16. Nissim, A. et al. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J. 13, 692-698 (1994).
17. D'Amato, R.J., Loughnan, M.S., Flynn, E. & Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91, 4082-4085 (1994).
18. Folli, S. et al. Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. Cancer Res. 54, 2643-2649 (1994).
19. Yarmush, M.L. et al. Antibody targeted photolysis. Crit. Rev. Ther. Drug Carrier Syst. 10, 197-252 (1993).
20. Rowe, P.M. Photodynamic therapy begins to shine. Lancet 351, 1496 (1998).
21. Levy, J. Photodynamic therapy. Trends Biotechnol. 13, 14-18 (1995).
22. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Arch. Ophthalmol. 112, 480-488 (1994).
23. Haimovici, R. et al. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr. Eye Res. 16, 83-90 (1997).
24. Schmidt-Erfurth, U. et al. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch. Clin. Exp. Ophthalmol. 236, 365-374 (1998).
25. Lu, X.M. et al. Sn-chlorin e6 antibacterial immunoconjugates. An in vitro and in vivo analysis. J. Immunol. Methods 156, 85-99 (1992).
26. Gavrieli, Y., Sherman, Y. & Ben-Sasson, S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol. 119, 493-501 (1992).
27. Regillo, C.D., Benson, W.E., Maguire, J.I. & Annesley, W.H. Jr. Indocyanine green angiography and occult choroidal neovascularization. Ophthalmology 101, 280-288 (1994).
28. Van den Bergh, H. On the evolution of some endoscopic light delivery systems for photodynamic therapy. Endoscopy 30, 392-407 (1998).
29. Wan, S., Parrish, J.A., Anderson, R.R. & Madden, M. Transmittance of nonionizing radiation in human tissues. Photochem. Photobiol. 34, 679-681 (1981).
30. Murdter, T.E. et al. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. Cancer Res. 57, 2440-2445 (1997).
31. Huston, J.S. et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85, 5879-5883 (1988).
32. Fattorusso, R. et al. NMR structure of the angiogenesis marker oncofoetal fibronectin ED-B domain. Structure 7, 381-390 (1999).